TDAC — Translational Development Acquisition Balance Sheet
0.000.00%
- $223.24m
- $222.80m
- 28
- 70
- 77
- 59
Annual balance sheet for Translational Development Acquisition, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|
Period Length: | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | 10-K |
Standards: | — | USG | USG |
Status: | Final | Final | Final |
Cash | |||
Cash and Short Term Investments | 0.002 | 0.002 | 0.438 |
Prepaid Expenses | |||
Total Current Assets | 0.054 | 0.002 | 0.65 |
Long Term Investments | |||
Other Long Term Assets | |||
Total Assets | 0.437 | 0.002 | 175 |
Accounts Payable | |||
Accrued Expenses | |||
Notes Payable / Short Term Debt | |||
Total Other Current Liabilities | |||
Total Current Liabilities | 0.459 | 0.51 | 0.21 |
Total Long Term Debt | |||
Total Debt | |||
Total Other Liabilities | |||
Total Liabilities | 0.459 | 0.51 | 6.25 |
Common Stock | |||
Additional Paid In Capital | |||
Retained Earnings (Accumulated Deficit) | |||
Total Equity | -0.022 | -0.508 | 169 |
Total Liabilities & Shareholders' Equity | 0.437 | 0.002 | 175 |
Total Common Shares Outstanding |